Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605533997 | ||
| 003 | CHVBK | ||
| 005 | 20210128100840.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9422-4 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9422-4 | ||
| 245 | 0 | 0 | |a Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data |h [Elektronische Daten] |c [Jenny Zheng, Erno van Schaick, Liviawati Wu, Philippe Jacqmin, Juan Perez Ruixo] |
| 520 | 3 | |a Osteoporosis is a chronic skeletal disease characterized by low bone strength resulting in increased fracture risk. New treatments for osteoporosis are still an unmet medical need because current available treatments have various limitations. Bone mineral density (BMD) is an important endpoint for evaluating new osteoporosis treatments; however, the BMD response is often slower and less profound than that of bone turnover markers (BTMs). If the relationship between BTMs and BMD can be quantified, the BMD response can be predicted by the changes in BTM after a single dose; therefore, a decision based on BMD changes can be informed early. We have applied a bone cycle model to a phase 2 denosumab dose-ranging study in osteopenic women to quantitatively link serum denosumab pharmacokinetics, BTMs, and lumbar spine (LS) BMD. The data from two phase 3 denosumab studies in patients with low bone mass, FREEDOM and DEFEND, were used for external validation. Both internal and external visual predictive checks demonstrated that the model was capable of predicting LS BMD at the denosumab regimen of 60mg every 6months. It has been demonstrated that the model, in combination with the changes in BTMs observed from a single-dose study in men, is capable of predicting long-term BMD outcomes (e.g., LS BMD response in men after 1year of treatment) in different populations. We propose that this model can be used to inform drug development decisions for osteoporosis treatment early via evaluating LS BMD response when BTM data become available in early trials. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Osteoporosis |2 nationallicence | |
| 690 | 7 | |a Pharmacokinetics |2 nationallicence | |
| 690 | 7 | |a Pharmacodynamics |2 nationallicence | |
| 690 | 7 | |a Bone remodeling |2 nationallicence | |
| 690 | 7 | |a Denosumab |2 nationallicence | |
| 700 | 1 | |a Zheng |D Jenny |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | |
| 700 | 1 | |a van Schaick |D Erno |u SGS Exprimo NV, Generaal de Wittelaan 19A b5, 2800, Mechelen, Belgium |4 aut | |
| 700 | 1 | |a Wu |D Liviawati |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | |
| 700 | 1 | |a Jacqmin |D Philippe |u SGS Exprimo NV, Generaal de Wittelaan 19A b5, 2800, Mechelen, Belgium |4 aut | |
| 700 | 1 | |a Perez Ruixo |D Juan |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/4(2015-08-01), 333-347 |x 1567-567X |q 42:4<333 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9422-4 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9422-4 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Zheng |D Jenny |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a van Schaick |D Erno |u SGS Exprimo NV, Generaal de Wittelaan 19A b5, 2800, Mechelen, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Wu |D Liviawati |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Jacqmin |D Philippe |u SGS Exprimo NV, Generaal de Wittelaan 19A b5, 2800, Mechelen, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Perez Ruixo |D Juan |u Pharmacokinetics and Drug Metabolism Division, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/4(2015-08-01), 333-347 |x 1567-567X |q 42:4<333 |1 2015 |2 42 |o 10928 | ||